全球适体市场规模、份额、成长分析，按类型（核酸和胜肽）、按应用（诊断、治疗）- 2024-2031 年产业预测

Global Aptamers Market Size, Share, Growth Analysis, By Type(Nucleic Acid and Peptide), By Application(Diagnostics, Therapeutics) - Industry Forecast 2024-2031

出版日期: 2024年04月02日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球适体市场规模为12.0亿美元，预计将从2023年的1.43亿美元成长到2031年的58.3亿美元，预测期间（2024-2031年）复合年增长率为19.2%。

适配体因其在生产、纯化和标靶药物递送方面的独特优势而引起了研究人员的极大兴趣，与抗体相比具有分子尺寸小、免疫原性低、成本效益高、副作用少等优点。这刺激了适体开发的创新，有可能扩大市场。儘管存在各种遗传变异，但目前的感染疗法缺乏有效性，因此需要先进的解决方案。基于 SELEX 技术的诊断试剂盒有望生产高亲和力中和剂，这可能会推动市场扩张。基于适配体的诊断试剂盒，与第二代基于DNA 适配体的适配体一样，提供经济高效的化学合成解决方案，例如EPIC 研究中使用的Soma Logic 的SomaScan Assay，可实现更深入的疾病了解并促进市场成长，以满足日益增长的需求。基于适配体的诊断解决方案体积小、特异性高、选择性高且功效高，是细胞层面疾病诊断的首选，可满足到 2040 年癌症诊断的预期成长。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

NeoVentures Biotechnology Inc. (United States)
Base Pair Biotechnologies, Inc. (United States)
Aptagen, LLC (United States)
SomaLogic, Inc. (United States)
Vivonics, Inc. (United States)
Aptamer Sciences, Inc. (United States)
TriLink BioTechnologies, LLC (United States)
AMS Biotechnology Europe Ltd. (United Kingdom)
Aptamer Group Ltd. (United Kingdom)
NOXXON Pharma AG (Germany)
AM Biotechnologies, LLC (United States)
Aptus Biotech SL (Spain)
Aptamer Group (United Kingdom)
Ophthotech Corporation (United States)
Vivonics, Inc. (United States)
ATDBio Ltd. (United Kingdom)
Base Pair Biotechnologies, Inc. (United States)
Am Biotechnologies, LLC (United States)
Aptamer Sciences, Inc. (United States)
Orla Protein Technologies Ltd. (United Kingdom)
Archemix Corp. (United States)
AptaMatrix (United States)

简介目录

Product Code: SQMIG35E2038

Global Aptamers Market size was valued at USD 1.20 billion in 2022 and is poised to grow from 1.43 USD billion in 2023 to USD 5.83 billion by 2031, at a CAGR of 19.2% during the forecast period (2024-2031).

Aptamers have attracted significant interest from researchers due to their distinct advantages in production, purification, and targeted drug delivery, offering benefits such as small molecular size, low immunogenicity, cost-effectiveness, and reduced side effects compared to antibodies. This has spurred innovation in aptamer development, potentially expanding the market. Despite various genetic variations, current therapies for infections lack effectiveness, prompting the need for advanced solutions. SELEX technology-based diagnostic kits offer promise in producing high-affinity neutralizers, likely driving market expansion. Aptamer-based diagnostic kits, like the second-generation DNA aptamer-based Aptamer, offer cost-effective and chemically synthesized solutions, exemplified by Soma Logic's SomaScan Assay, utilized in the EPIC research, enabling deeper disease understanding and facilitating market growth to meet rising cancer diagnostic demands predicted by Cancer Research UK. With their small size, high specificity, selectivity, and efficacy, aptamer-based diagnostic solutions are preferred in cellular-level disease diagnosis, catering to the anticipated increase in cancer diagnoses by 2040.

Top-down and bottom-up approaches were used to estimate and validate the size of the global aptamers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Aptamers Market Segmental Analysis

Global Aptamers Market is segmented on the basis of type, application and region. By type, the market is segmented into nucleic acid and peptide. By application, market is segmented into diagnostics, therapeutics, research & development, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Aptamers Market

Aptamers are integral to personalized medicine due to their ability to selectively bind to various target molecules like proteins, peptides, and small molecules. With the rising focus on tailored therapies and precision medicine, there's a heightened need for aptamers owing to their distinct benefits such as exceptional specificity, minimal immunogenicity, and customizable attributes. By facilitating precise molecular recognition, aptamers pave the way for the formulation of individualized treatment approaches, thereby playing a pivotal role in advancing personalized medicine strategies.

Restraints in the Global Aptamers Market

The advancement of the aptamers market faces obstacles due to intellectual property (IP) challenges, wherein patent rights and licensing agreements concerning aptamers and associated technologies may constrain their commercialization potential, particularly for specific applications or targets. The intricate IP landscape surrounding aptamer-based technologies introduces legal uncertainties and potential obstacles for market participants, impeding their growth prospects.

Market Trends of the Global Aptamers Market

The primary technique for aptamer selection, known as SELEX (Systematic Evolution of Ligands by Exponential Enrichment), is increasingly emphasizing optimization and automation to bolster efficiency, cut down expenses, and enhance the quality of aptamers. Innovations in high-throughput screening, microfluidics, and robotics are being harnessed to streamline the aptamer development workflow, thus democratizing and scaling up the process for wider accessibility.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Aptamers Market by Type

Market Overview
Nucleic Acid and Peptide

Global Aptamers Market by Application

Market Overview
Diagnostics
Therapeutics
Research & Development
Others

Global Aptamers Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

NeoVentures Biotechnology Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Base Pair Biotechnologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptagen, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SomaLogic, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vivonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TriLink BioTechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AMS Biotechnology Europe Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Group Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NOXXON Pharma AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AM Biotechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptus Biotech S.L. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Group (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ophthotech Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vivonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ATDBio Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Base Pair Biotechnologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Am Biotechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orla Protein Technologies Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Archemix Corp. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AptaMatrix (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments